SOPHiA GENETICS has announced a new global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. The agreement links SOPHiA GENETICS' diagnostic capabilities with AstraZeneca's work in cancer treatment, focusing on tests designed to support targeted therapy use.
According to the announcement, the partnership will cover the full process from development through validation and deployment. Companion diagnostics are commonly used alongside specific medicines to help match therapies with the right clinical setting, making them an important part of precision oncology strategies.
The collaboration was announced from Boston and Rolle, Switzerland, underscoring the international scope of the effort. By centering on two companion diagnostics, the companies are signaling a targeted approach rather than a broad platform deal, with the work aimed at supporting precision oncology therapies on a global basis.
The news adds to growing industry momentum around combining advanced diagnostics with cancer drug development. For SOPHiA GENETICS and AstraZeneca, the partnership highlights continued investment in precision medicine tools that connect testing, validation, and treatment support in oncology.
